Zentalis Pharmaceuticals (ZNTL) Current Assets (2019 - 2026)

Zentalis Pharmaceuticals' Current Assets history runs 8 years deep, the most recent figure standing at $218.1 million for Q1 2026.

• On a quarterly basis, Current Assets fell 36.39% year-over-year to $218.1 million in Q1 2026; TTM through Mar 2026 was $218.1 million, a 36.39% decrease from a year earlier, with the FY2025 full-year figure at $253.2 million, down 34.42% from the prior year.
• Current Assets slipped to $218.1 million in Q1 2026 per ZNTL's latest filing, from $253.2 million in the prior quarter.
• Across five years, Current Assets topped out at $563.9 million in Q2 2023 and bottomed at $218.1 million in Q1 2026.
• The 5-year median for Current Assets is $410.2 million (2023), against an average of $399.9 million.
• Across the five-year window, Current Assets jumped 80.24% in 2022 and sank 36.39% in 2026, its largest moves.
• Year by year, Current Assets stood at $451.9 million in 2022, then climbed by 9.91% to $496.7 million in 2023, then declined by 22.28% to $386.1 million in 2024, then plunged by 34.42% to $253.2 million in 2025, then retreated by 13.86% to $218.1 million in 2026.
• Per Business Quant, the three latest ZNTL Current Assets figures stand at $218.1 million (Q1 2026), $253.2 million (Q4 2025), and $288.3 million (Q3 2025).